
Eli Lilly’s Emgality shows positive Phase 3 results in treatment of migraine
pharmafile | May 8, 2019 | News story | Research and Development | Eli Lilly, Emgality, cluster headache, headache, migraine, pharma
Eli Lilly has announced positive results from the Phase 3 EVOLVE-1 and EVOLVE-2 trials looking into Emgality (galcanezumab-gnlm) for the treatment of episodic migraine.
The drug was found to reduce the number of migraine headache days patients experienced each month, in comparison to placebo.
Patients – who were categorised as either low-frequency (four to seven migraine days a month) or high-frequency (eight to 14 monthly migraine days a month) – were given either 120mg or 240mg doses of Lilly’s Emgality.
Both doses were found to reduce the number of migraine days in both the low-frequency and high-frequency subgroups in comparison to placebo.
Lilly Bio-Medicines Neurology Development vice-president Gudarz Davar commented: “Migraine causes people to suffer from substantial pain and impairment, no matter how frequently they occur.”
“These collective analyses of more than 1,700 patients with episodic migraine from our Phase 3 Emgality programme reflect our continued commitment to aid people living with this serious neurologic disorder.”
The FDA is also currently reviewing the monoclonal antibody, which specifically targets calcitonin gene-related peptide (CGRP), as a preventative treatment of episodic cluster headache in adults.
Louis Goss
Related Content

Migraine annual economic and quality-of-life burden in UK
Migraine affects an estimated 280,000 people across Greater Manchester and creates an annual economic and …

One in three UK women with migraine say symptoms taken less seriously
One in three UK women who have experienced migraine say they believe their symptoms are …

Pharma sees climate disruption as growing supply-chain risk
Nine in ten pharmaceutical companies across the UK and G7 countries expect climate-related disruption to …






